

1 ENGROSSED SENATE
2 BILL NO. 1467

By: David of the Senate

and

3
4 Caldwell (Chad) of the
House

5
6 An Act relating to the state Medicaid program;
7 requiring Oklahoma Health Care Authority to conduct
8 certain annual review; stating purpose; requiring
9 review to include certain criteria; directing
10 Authority to seek public input; requiring utilization
of Oklahoma State Health Information Network and
Exchange to extent practicable; directing submission
and publication of annual report; providing for
codification; and providing an effective date.

11

12 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

13 SECTION 1. NEW LAW A new section of law to be codified
14 in the Oklahoma Statutes as Section 5026.1 of Title 63, unless there
15 is created a duplication in numbering, reads as follows:

16 A. The Oklahoma Health Care Authority shall conduct an annual
17 review of all medications and forms of treatment for sickle cell
18 disease and services for enrollees with a diagnosis of sickle cell
19 disease. The purpose of the annual review is to determine if the
20 available covered medications, treatments, and services are adequate
21 to meet the needs of enrollees with a diagnosis of sickle cell
22 disease, and whether the Authority should seek to add or recommend
23 additional medications, treatments, or services.

24 B. The review shall include, but not be limited to:

1 1. The extent to which healthcare transitional programs covered
2 under the state Medicaid program prepare, transfer, and integrate
3 emerging adults into the adult care setting from a pediatric
4 setting;

5 2. The extent to which emergency department providers are
6 adequately trained and otherwise prepared to treat and manage sickle
7 cell patients presenting with vaso-occlusive crises including but
8 not limited to the extent to which providers follow clinically
9 validated algorithms and protocols regarding such treatment and
10 management;

11 3. The extent to which sickle cell patients covered under the
12 state Medicaid program are entitled to receive the same standard of
13 care when referred or transferred to an out-of-state facility, and
14 the extent to which the state reimburses such patients for
15 reasonable interstate travel costs; and

16 4. Any additional areas identified by the Authority that impact
17 the care and treatment of individuals in this state living with
18 sickle cell disease or sickle cell trait.

19 C. When conducting the annual review required by this section,
20 the Authority shall solicit and consider input from the general
21 public, with specific emphasis on seeking input from persons or
22 groups with knowledge and experience in the area of sickle cell
23 disease treatment.

24

1 D. To the extent practicable, the Authority shall utilize the
2 Oklahoma State Health Information Network and Exchange created under
3 Section 1-133 of Title 63 of the Oklahoma Statutes to collect
4 information for the purpose of implementing this section.

5 E. On or before January 15, 2023, and on or before January 15
6 each year thereafter, the Authority shall submit a report to the
7 President Pro Tempore of the Senate and the Speaker of the House of
8 Representatives for distribution to the appropriate subject matter
9 committees that details the Authority's findings from the annual
10 review required by this section and any recommendations to the
11 Legislature based upon those findings. The Authority shall publish
12 the annual report required by this subsection to its website in a
13 manner accessible by the general public.

14 SECTION 2. This act shall become effective November 1, 2022.

15 Passed the Senate the 23rd day of March, 2022.

16

17

Presiding Officer of the Senate

18

19 Passed the House of Representatives the ____ day of _____,

20 2022.

21

22

Presiding Officer of the House
of Representatives

23

24